This article is more than 5 years old. Information may no longer be current.
Iris Pharma merges with Clirophtha to form ophthalmology-focused contract research organization
Click Here to Manage Email Alerts
NICE, France — Iris Pharma has completed a merger with Clirophtha, a contract research organization in Europe and North America that specializes in ophthalmic clinical trials, according to a release from Iris Pharma.
Operating under the Iris Pharma name, the merger establishes a worldwide drug development services provider devoted entirely to ophthalmology, the release said.
"The cumulative expertise and experience from both companies guarantees that the new Iris Pharma company has excellent know-how and knowledge of each step of drug development, from pre-formulation and in vivo research to phase 4 and medico-marketing surveys, as well as a global overview of the whole process," Thierry Caillaud, business development director of Iris Pharma, said in the release.